IRIS
MADEDDU, Giordano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.304
AS - Asia 7.954
EU - Europa 7.159
SA - Sud America 4.531
Continente sconosciuto - Info sul continente non disponibili 597
AF - Africa 320
OC - Oceania 28
AN - Antartide 1
Totale 41.894
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.817
BR - Brasile 4.042
SG - Singapore 3.526
IT - Italia 3.337
CN - Cina 1.894
UA - Ucraina 1.029
DE - Germania 708
HK - Hong Kong 673
VN - Vietnam 658
FR - Francia 460
GB - Regno Unito 300
FI - Finlandia 297
CA - Canada 206
SE - Svezia 203
AR - Argentina 167
IN - India 154
NL - Olanda 153
BD - Bangladesh 136
RU - Federazione Russa 135
TR - Turchia 127
IQ - Iraq 122
MX - Messico 118
EC - Ecuador 91
ZA - Sudafrica 89
PK - Pakistan 73
PL - Polonia 72
ES - Italia 71
UZ - Uzbekistan 70
JP - Giappone 68
MA - Marocco 68
CZ - Repubblica Ceca 60
CO - Colombia 57
VE - Venezuela 57
RO - Romania 48
NP - Nepal 44
BE - Belgio 42
AE - Emirati Arabi Uniti 41
ID - Indonesia 40
KR - Corea 40
TN - Tunisia 40
AT - Austria 34
PY - Paraguay 34
KE - Kenya 32
CH - Svizzera 31
IE - Irlanda 31
SA - Arabia Saudita 31
JO - Giordania 28
AU - Australia 27
AZ - Azerbaigian 26
CR - Costa Rica 26
CL - Cile 25
IL - Israele 25
LT - Lituania 25
JM - Giamaica 23
KZ - Kazakistan 23
PE - Perù 23
RS - Serbia 23
UY - Uruguay 23
KG - Kirghizistan 20
DO - Repubblica Dominicana 17
HN - Honduras 17
PH - Filippine 17
AL - Albania 16
MY - Malesia 16
DZ - Algeria 15
EG - Egitto 15
OM - Oman 15
PS - Palestinian Territory 15
SN - Senegal 15
BG - Bulgaria 14
EU - Europa 14
IR - Iran 14
LB - Libano 13
PA - Panama 13
GT - Guatemala 12
NI - Nicaragua 11
TT - Trinidad e Tobago 10
XK - ???statistics.table.value.countryCode.XK??? 10
HU - Ungheria 9
AM - Armenia 8
BO - Bolivia 8
BY - Bielorussia 8
MD - Moldavia 8
CW - ???statistics.table.value.countryCode.CW??? 7
ET - Etiopia 7
GR - Grecia 7
MK - Macedonia 7
SV - El Salvador 7
NG - Nigeria 6
PT - Portogallo 6
A2 - ???statistics.table.value.countryCode.A2??? 5
BN - Brunei Darussalam 5
GP - Guadalupe 5
LU - Lussemburgo 5
PR - Porto Rico 5
QA - Qatar 5
SK - Slovacchia (Repubblica Slovacca) 5
AO - Angola 4
CI - Costa d'Avorio 4
GD - Grenada 4
Totale 41.247
Salva come PNG Salva come JPEG
Città #
Dallas 9.395
Singapore 1.980
San Jose 1.493
Chandler 1.267
Ashburn 1.041
Council Bluffs 700
Hong Kong 665
Jacksonville 582
Beijing 476
Santa Clara 472
Princeton 399
Columbus 387
Milan 363
New York 344
Rome 283
São Paulo 264
Lauterbourg 241
Ho Chi Minh City 214
Los Angeles 207
Munich 198
Nanjing 195
Dearborn 190
Hanoi 165
Wilmington 159
Shanghai 156
Sassari 152
Rio de Janeiro 131
Helsinki 128
Boardman 123
Belo Horizonte 114
Ann Arbor 106
Nanchang 82
Naples 81
The Dalles 81
Brasília 80
Phoenix 74
Curitiba 71
Shenyang 70
Atlanta 62
Tashkent 60
Cagliari 59
Campinas 59
Orem 59
Tokyo 59
Buffalo 58
Montreal 58
Tianjin 58
Brno 56
Porto Alegre 56
Warsaw 56
Florence 55
Denver 53
Frankfurt am Main 53
San Francisco 53
Toronto 53
Brooklyn 52
Turin 48
Woodbridge 48
Changsha 43
Hebei 43
Johannesburg 43
London 43
Miano 43
Baghdad 42
Chicago 42
Brussels 41
Palermo 41
Nuremberg 40
Salvador 40
Fortaleza 39
The Villages 38
Chennai 37
Guarulhos 37
Guayaquil 37
Houston 36
Jinan 35
Seoul 35
Mexico City 34
Manchester 33
Dhaka 32
Poplar 32
São José dos Campos 32
Goiânia 31
Zhengzhou 31
Bologna 30
Da Nang 30
Guangzhou 30
São Bernardo do Campo 30
Turku 30
Amsterdam 29
Boston 29
Bari 28
Nairobi 28
Haiphong 27
Istanbul 27
Jiaxing 27
Santo André 27
Sorocaba 27
Amman 26
Lahore 26
Totale 25.675
Salva come PNG Salva come JPEG
Nome #
CASE REPORT: MIOCARDITE ACUTA DA CITOMEGALOVIRUS IN GIOVANE PAZIENTE IMMUNOCOMPETENTE 2.155
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation 859
Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives 674
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997–2022: Data From the Icona Cohort 672
Tuberculosis-Induced Immune-Mediated Necrotizing Myopathy: A Challenging Case Scenario in a Non-Endemic Country 585
CD4/CD8 Ratio Increase in Female Living with HIV Switching to Cabotegravir-Rilpivirine: A Real-Life 24 Weeks Evaluation 552
Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections– results from a retrospective multicentre study 542
Neuropsychiatric adverse events in people with HIV initiating a new integrase strand transfer inhibitor-based regimen in Italy: findings from the NEURO-INSTI study 445
PARVOVIRUS B19 E POLIMIALGIA REUMATICA: THE BUTTERFLY EFFECT 419
Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study 296
Assessing the Accuracy, Completeness and Safety of ChatGPT-4o Responses on Pressure Injuries in Infants: Clinical Applications and Future Implications 294
Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis? 293
How Little Do We Know about HIV and STIs Prevention? Results from a Web-Based Survey among the General Population 276
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort 276
Clinical use of dalbavancin in the Italian SUSANA cohort (SUrveillance of SAfety and outcome of New Antibiotics) 275
Efficacy and safety of B/F/TAF in naïve people with HIV: real life data from the SHiNeSHiC research group 274
Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options 263
New treatment strategies for HIV-positive cancer patients undergoing anticancer medical treatment: update of the literature 254
Fluoroquinolones and Biofilm: A Narrative Review 252
Enzyme biosensors for biomedical applications: Strategies for safeguarding analytical performances in biological fluids 239
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 237
Efficacy and tolerability of antiretroviral therapy: focus on people with HIV or on PrEP 235
99mTc-tetrofosmin SPECT in solitary pulmonary nodule evaluation 234
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV 233
Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis? 225
A case of vasculitis-like skin eruption associated with COVID-19 220
Activation of endogenous retroviruses of the HERV-W family by Epstein Barr virus in vitro and in vivo: a dual virus model as the missing link with multiple sclerosis 217
Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study 210
Underserved populations and bacterial and protozoal sexually transmitted infections: a lost health-care opportunity 210
The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients 208
Ebola virus disease: Case management in the Institute of Infectious Diseases, University Hospital of Sassari, Sardinia, Italy. 208
Analisi delle Dual Therapy nei pazienti con HIV: Aspetti farmacoeconomici-epidemiologici e clinici 202
Active Case Finding for Communicable Diseases in Prison Settings: Increasing Testing Coverage and Uptake Among the Prison Population in the European Union/European Economic Area 199
Dalbavancin two dose regimen for the treatment of prosthetic joint infections: new possible options for difficult to treat infectious diseases 197
Epidemiology, Clinical Aspects, Laboratory Diagnosis and Treatment of Rickettsial Diseases in the Mediterranean Area During COVID-19 Pandemic: A Review of the Literature 194
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. 193
A longitudinal Study on body compositionin HIV –infected patients receiving HAART. 193
Mucocutaneous leishmniasis as presentation of HIV infection in Sardinia, insular Italy 191
Acute respiratory distress syndrome due to influenza virus A/H1N1v in a patient with HIV/HCV co-infection 189
Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study 186
Correlations between IL-6 serum level and olfactory dysfunction severity in COVID-19 patients: a preliminary study 184
HEPATOCELLULAR CARCINOMA DEVELOPMENT IN A PATIENT WITH HCV INFECTION AFTER ERADICATION WITH DIRECT-ACTING ANTIVIRAL AGENTS 182
Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era 179
Does Angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience 178
A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA 177
Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia, Italy 173
The additional role of 18F-FDG PET/CT in prosthetic valve endocarditis 172
Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study 171
The burden of HIV-Associated neurocognitive disorder (HAND) in post-HAART era: Amultidisciplinary review of the literature 171
The De Ritis ratio as prognostic biomarker of in-hospital mortality in COVID-19 patients 170
Targeted therapies in cholangiocarcinoma: emerging evidence from clinical trials 167
QuantiFERON TB Gold: a new method for latent tuberculosis infection 166
Assessing ChatGPT’s Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity 165
Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy 165
Correlations Between Olfactory Psychophysical Scores and SARS-CoV-2 Viral Load in COVID-19 Patients 165
Adverse skin reactions in course of combined antiretroviral therapy 165
Trends in the European HIV/AIDS epidemic: a perspective from Italy 165
Immune response induced by Epstein-Barr virus and Mycobacterium avium subsp. paratuberculosis peptides in current and past infectious mononucleosis: a risk for multiple sclerosis? 164
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B 162
Natalizumab therapy modulates miR-155, miR-26a and proinflammatory cytokine expression in MS patients 162
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project 159
Cytological and histological diagnosis of lung cancer in Sardinia and Italy in the 1990s 159
Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors 158
Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study. 158
Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases 157
Meningite linfomatosa in un paziente con linfoma plasmoblastico del cavo orale HIV-relato: ruolo della citarabina liposomiale. 156
Mood Reactive Disorders among COVID-19 Inpatients: Experience from a Monocentric Cohort 156
Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients 155
Assessing ChatGPT’s theoretical knowledge and prescriptive accuracy in bacterial infections: a comparative study with infectious diseases residents and specialists 154
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 154
Chronic viral hepatitis in the italian prison setting: Prevalence, outcomes, literature needs and perspectives 154
Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression 154
Pneumococcal pneumonia: clinical features, diagnosis and management in HIV-infected and HIV non infected patients 153
Body composition change in hiv-infected patients treated with HAART: a longitudinal DEXA study. 153
Editorial - Non AIDS-defining malignancies: a new epidemic in HIV-infected population for the upcoming decades? 152
Proteomic characterization of hepatitis C eradication: enzyme switch in the healing liver. 151
Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? 151
Arboviral infections in Egyptian and Sardinian children and adults with aseptic meningitis and meningo-encephalitis 150
Body fat changes and mitochondrial alterations during HBV treatment: A warning for long term administration. 150
Circulation of SARS-CoV-2 Among Asylum Seekers: A Real-Life Experience to Address Health Equity in Piacenza, Italy 149
DNMT1 modulation in chronic hepatitis B patients and hypothetic influence on mitochondrial DNA methylation status during long-term nucleo(t)side analogs therapy 149
Hepatic echinococcosis: clinical and therapeutic aspects. 149
Body composition evaluation by DEXA in the follow up of HIV patients treted with HAART. 149
Bacterial community-acquired pneumonia in HIV-infected patients 148
Effectiveness of Vitamin D Supplements among Patients Hospitalized for COVID-19: Results from a Monocentric Matched-Cohort Study 147
Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study 146
Kidney disease in HIV-infected patients. 146
Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy 146
Utilizzo di EVG/COBI/FTC/TDF in una paziente con viremia elevata e cirrosi HCV-correlata 145
Tuberculosis Screening before Anti–Hepatitis C Virus Therapy in Prisons 143
Systemic inflammatory markers and psychophysical olfactory scores in coronavirus disease 2019 patients: is there any correlation? 143
HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project 142
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 142
Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort 142
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. 141
Neurocognitive performance and cardiovascular risk in a cohort of HIV-infected patients 140
Feasibility and efficacy of eight weeks Glecaprevir/Pibrentasvir to treat incarcerated viremic HCV patients: a case-control study 140
Vaccinations in prison settings: A systematic review to assess the situation in EU/EEA countries and in other high income countries 139
Bone safety of dolutegravir-containing regimens in people living with HIV: Results from a real-world cohort 139
Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report 138
Totale 23.436
Salva come PNG Salva come JPEG
Categoria #
all - tutte 147.552
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 147.552
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022924 0 0 0 26 26 32 40 63 83 72 143 439
2022/20232.522 239 209 68 414 208 404 37 274 402 47 130 90
2023/20241.209 139 72 56 40 293 114 35 79 17 48 101 215
2024/20259.092 150 144 492 308 492 405 674 1.560 2.882 1.231 517 237
2025/202619.005 655 3.112 7.385 1.796 1.431 625 1.840 371 580 689 338 183
2026/20274.268 484 952 1.213 1.619 0 0 0 0 0 0 0 0
Totale 41.894